85,059 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Castlekeep Investment Advisors LLC

Castlekeep Investment Advisors LLC purchased a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 85,059 shares of the biopharmaceutical company's stock, valued at approximately $1,775,000. Castlekeep Investment Advisors LLC owned 0.07% of Catalyst Pharmaceuticals as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $27,000. Farther Finance Advisors LLC lifted its position in Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $65,000. KBC Group NV boosted its stake in shares of Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after purchasing an additional 1,542 shares during the period. Finally, Quarry LP bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth approximately $104,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX traded down $0.10 during mid-day trading on Thursday, hitting $24.44. 353,190 shares of the stock traded hands, compared to its average volume of 1,255,681. The company has a market cap of $2.98 billion, a price-to-earnings ratio of 20.71, a PEG ratio of 3.31 and a beta of 0.70. The stock has a fifty day moving average price of $23.61 and a 200-day moving average price of $22.59. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.75 and a 52 week high of $26.16.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CPRX shares. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Stephens reissued an "overweight" rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Robert W. Baird lifted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Finally, Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $32.29.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 351,879 shares of company stock valued at $8,214,815. Corporate insiders own 10.40% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.